Cardiovascular safety of rosiglitazone
- 1 June 2007
- journal article
- Published by Elsevier in The Lancet
- Vol. 369 (9578) , 1995-1996
- https://doi.org/10.1016/s0140-6736(07)60824-1
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular CausesNew England Journal of Medicine, 2007
- Rosiglitazone and Cardiovascular RiskNew England Journal of Medicine, 2007
- Glycemic Durability of Rosiglitazone, Metformin, or Glyburide MonotherapyNew England Journal of Medicine, 2006
- Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trialThe Lancet, 2006
- Rationale, Design, and Methods for Glycemic Control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) TrialThe American Journal of Cardiology, 2006
- Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocolDiabetologia, 2005